Skip to main content
. Author manuscript; available in PMC: 2022 Jun 27.
Published in final edited form as: Leuk Res. 2015 Jul 2;39(9):984–989. doi: 10.1016/j.leukres.2015.05.015

Fig. 2.

Fig. 2.

In vitro flow cytometry apoptosis analysis shows an additive effect of treatment with pazopanib and cytarabine. (A) KG-1 cells exposed to pazopanib and cytarabine demonstrate modest reduction in viability by XTT assay. In combination, the effect is additive, significantly decreasing viability of AML cells relative to controls. *p-values <0.05 for all treatment samples, compared to untreated control. (B) In the presence of an EC feeder layer, the addictive effect of pazopanib and cytarabine on AML cells persists. *p-values <0.05 for all treatment samples, compared to untreated control. (C) Western blot of phosphorylated SRC, a downstream target of RTK signaling, shows a dose-dependent decrease in phosphorylation with pazopanib exposure.